Genmab A/S is a solid buy with undervalued stock, robust royalties, and blockbuster ADC potential. Click for my look at GMAB ...

Against a backdrop of rising costs, workforce shortages and fragmented care, the Oracle Health and Life Sciences Summit convened leaders who are tackling these challenges head-on. Among the most ...

The commercial success of existing lipid-lowering medications highlights the enormous market potential for effective ...

Offshore structures constantly face threats from severe environmental forces—including strong winds, large waves, and earthquakes. These forces seriously ...